Samuel Barker - Cyclacel Pharmaceuti Director

CYCC
 Stock
  

USD 0.84  0.05  5.62%   

  Director
Dr. Samuel L. Barker, Ph.D., serves as Independent Director of the Company. Dr. Barker has served as a director of the Company since September 2014. In 2001, Dr. Barker cofounded Clearview Projects, Inc., a provider of partnering and transaction services to biopharmaceutical companies, where he worked until September 2010, having served as its president and chief executive officer from 2003 to 2004. Dr. Barker served in a series of leadership positions at BristolMyers Squibb Company until his retirement in 1999. His positions at BristolMyers Squibb included service as executive vice president, Worldwide Franchise Management and Strategy during 1998 president, United States Pharmaceuticals from 1992 to 1998 and president, BristolMyers Squibb Intercontinental Commercial Operations from 1989 to 1991. Prior to 1989, Dr. Barker held executive positions in research and development, manufacturing, business development and operations planning at Squibb Pharmaceuticals. Dr. Barker has served as a director Lexicon Pharmaceuticals, Inc. since 2001 and served as chairman from 2005 to 2012. Dr. Barker also served as a director of Cadence Pharmaceuticals, Inc. from 2006 to 2014 and of AtheroGenics, Inc. from 2005 to 2009
Age: 75  Director Since 2014      
908 517 7330  https://www.cyclacel.com
Barker received his B.S. from Henderson State College, his M.S. from the University of Arkansas and his Ph.D. from Purdue University.

Cyclacel Pharmaceuti Management Efficiency

Cyclacel Pharmaceuti has return on total asset (ROA) of (38.07) % which means that it has lost $38.07 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (51.66) %, meaning that it created substantial loss on money invested by shareholders. Cyclacel Pharmaceuti management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 113 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Cyclacel Pharmaceuti has a current ratio of 6.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Cyclacel Pharmaceuti until it has trouble settling it off, either with new capital or with free cash flow. So, Cyclacel Pharmaceuti's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cyclacel Pharmaceuti sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cyclacel to invest in growth at high rates of return. When we think about Cyclacel Pharmaceuti's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Arthur RyanRegeneron Pharmaceuticals
2003
David AltshulerVertex Pharmaceutic
2015
Sangeeta BhatiaVertex Pharmaceutic
2015
Yuchun LeeVertex Pharmaceutic
2012
Alan GarberVertex Pharmaceutic
2017
Lloyd CarneyVertex Pharmaceutic
2019
Michael BrownRegeneron Pharmaceuticals
1991
Bruce SachsVertex Pharmaceutic
2017
Sigmar GabrielSiemens Ag ADR
2018
Joseph GoldsteinRegeneron Pharmaceuticals
1991
Terrence KearneyVertex Pharmaceutic
2011
Christine PoonRegeneron Pharmaceuticals
2010
Margaret McGlynnVertex Pharmaceutic
2011
Alfred GilmanRegeneron Pharmaceuticals
1990
Clotilde DelbosSiemens Ag ADR
2018
Elaine UllianVertex Pharmaceutic
2011
George SingRegeneron Pharmaceuticals
1988
Marc TessierLavigneRegeneron Pharmaceuticals
2011
Sylvie BeaupuySiemens Ag ADR
2018
Mariel SchumannSiemens Ag ADR
2018
Baudouin ProtSiemens Ag ADR
2018
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Cyclacel Pharmaceuti (CYCC) is traded on NASDAQ Exchange in USA and employs 12 people.

Cyclacel Pharmaceuti Leadership Team

Elected by the shareholders, the Cyclacel Pharmaceuti's board of directors comprises two types of representatives: Cyclacel Pharmaceuti inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cyclacel. The board's role is to monitor Cyclacel Pharmaceuti's management team and ensure that shareholders' interests are well served. Cyclacel Pharmaceuti's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cyclacel Pharmaceuti's outside directors are responsible for providing unbiased perspectives on the board's policies.
Nicholas Bacopoulos, Independent Director
Lloyd Sems, Independent Director
David UPrichard, Independent Chairman of the Board
Samuel Barker, Director
Christopher Henney, Independent Vice Chairman of the Board
Judy Chiao, Vice President - Clinical Development and Regulatory Affairs
Gregory Hradsky, Independent Director
John Banham, Independent Director
Robert Spiegel, Independent Director
Spiro Rombotis, CEO and President and Executive Director
Paul McBarron, COO, CFO, Principal Accounting Officer, Executive VP of Fin. and Admin., Secretary and Executive Director

Cyclacel Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cyclacel Pharmaceuti a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cyclacel Pharmaceuti in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cyclacel Pharmaceuti's short interest history, or implied volatility extrapolated from Cyclacel Pharmaceuti options trading.

Pair Trading with Cyclacel Pharmaceuti

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclacel Pharmaceuti position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuti will appreciate offsetting losses from the drop in the long position's value.

Moving against Cyclacel Pharmaceuti

-0.67GEOGeo Group Normal TradingPairCorr
-0.57MRNAModerna Potential GrowthPairCorr
-0.55AZPNAspen Technology Sell-off TrendPairCorr
-0.55JPMJP Morgan Chase Fiscal Year End 13th of January 2023 PairCorr
The ability to find closely correlated positions to Cyclacel Pharmaceuti could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclacel Pharmaceuti when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclacel Pharmaceuti - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclacel Pharmaceuti to buy it.
The correlation of Cyclacel Pharmaceuti is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclacel Pharmaceuti moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclacel Pharmaceuti moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclacel Pharmaceuti can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Cyclacel Pharmaceuti information on this page should be used as a complementary analysis to other Cyclacel Pharmaceuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Cyclacel Stock analysis

When running Cyclacel Pharmaceuti price analysis, check to measure Cyclacel Pharmaceuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuti is operating at the current time. Most of Cyclacel Pharmaceuti's value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cyclacel Pharmaceuti's price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuti to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Is Cyclacel Pharmaceuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuti. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
10.5 M
Return On Assets
(0.42) 
Return On Equity
(0.60) 
The market value of Cyclacel Pharmaceuti is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuti's value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuti's market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Cyclacel Pharmaceuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.